People use propionyl-L-carnitine for leg pain during exercise due to poor blood flow (intermittent claudication), congestive heart failure (CHF), chest pain (angina), low levels of testosterone in older men, inflammatory bowel disease (including Crohn disease and ulcerative colitis), and many other conditions, but there is no good scientific evidence to support most of these uses.
How does it work ?
Uses & Effectiveness ?
Possibly Effective for
- Low levels of testosterone in older men. Taking propionyl-L-carnitine by mouth in combination with acetyl-L-carnitine for six months seems to improve sexual performance, depression, and tiredness in older men. Taking this combination seems to work about as well as taking the chemical testosterone.
- Chest pain (angina). Taking propionyl-L-carnitine by mouth seems to help people with angina walk farther. In some people, it might reduce how often they feel chest pain.
- Heart disease. When given with a needle in the vein, propionyl-L-carnitine helps the heart pump better in people with ischemic heart disease.
- Heart failure and fluid build up in the body (congestive heart failure or CHF). Taking propionyl-L-carnitine seems to improve how the heart works in people with mild or moderate CHF. It also seems to help people with this disease walk farther.
- Erectile dysfunction (ED). Taking propionyl-L-carnitine along with sildenafil (Viagra) may work better than taking sildenafil alone in men with diabetes and ED. Also, taking a specific product that contains propionyl-L-carnitine and other ingredients seems to help with sexual performance in men with ED.
- Leg pain during exercise due to poor blood flow (intermittent claudication). Propionyl-L-carnitine taken by mouth or given with a needle in the vein seems to help people with leg pain walk farther than they otherwise could. Propionyl-L-carnitine seems to work best for people with more severe disease.
- A disease that causes curved, painful erections (Peyronie disease). The combination of propionyl-L-carnitine and injection of a medication called verapamil seems to improve sexual performance, slow down worsening of the disease, and possibly prevent surgery in people with Peyronie's disease.
- A type of inflammatory bowel disease (ulcerative colitis). Propionyl-L-carnitine might reduce symptoms in people with ulcerative colitis who are also using other medications. It might even help them go into remission, which means that the symptoms go away.
Insufficient Evidence for
- Athletic performance. Taking a specific ingredient called glycine propionyl-L-carnitine might increase cycling strength. But taking too much glycine propionyl-L-carnitine or taking it too often might make exercise harder.
- A type of inflammatory bowel disease (Crohn disease). Early research suggests that using propionyl-L-carnitine reduces symptoms in people with Crohn's disease.
- Chronic fatigue syndrome (CFS). Developing research suggests that propionyl-L-carnitine might improve general tiredness in patients with CFS. Interestingly, the combination of propionyl-L-carnitine and acetyl-L-carnitine appears to be less effective than either supplement alone.
- Male-pattern baldness (androgenic alopecia).
- Circulatory problems caused by diabetes.
- Other conditions.
When given by IV: Propionyl-L-carnitine is LIKELY SAFE for most people when given intravenously (by IV) by a healthcare professional.
Special Precautions and Warnings
Underactive thyroid (hypothyroidism): There is a concern that propionyl-L-carnitine might make hypothyroidism worse or thyroid hormone treatment less effective. This is because a related chemical, L-carnitine, seems to interfere with thyroid hormone. If you have hypothyroidism, don't take propionyl-L-carnitine.
Seizures: Some people who have a history of seizures have reported an increase in the number and severity of seizures after taking L-carnitine by mouth or when given with a needle in the vein (by IV). There is a concern that this might also occur with propionyl-L-carnitine, because it is a similar chemical.
Acenocoumarol (Sintrom) interacts with PROPIONYL-L-CARNITINE
Acenocoumarol (Sintrom) is used to slow blood clotting. Propionyl-L-carnitine might increase the effects of acenocoumarol (Sintrom). Increasing the effects of acenocoumarol (Sintrom) might slow blood clotting too much and cause bruising and bleeding. The dose of your acenocoumarol (Sintrom) might need to be changed.
Warfarin (Coumadin) interacts with PROPIONYL-L-CARNITINE
Warfarin (Coumadin) is used to slow blood clotting. Propionyl-L-carnitine might increase the effects of warfarin (Coumadin) and increase the chances of bruising and bleeding. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.
Be cautious with this combination
- For heart disease: 500-2000 mg propionyl-L-carnitine twice daily.
- For chest pain (angina): 500 mg propionyl-L-carnitine three times daily.
- For low levels of testosterone in older men: 2 grams of propionyl-L-carnitine and 2 grams of acetyl-L-carnitine daily.
- For erectile dysfunction (ED): 2 grams of propionyl-L-carnitine daily along with 50 mg of sildenafil (Viagra) given twice weekly. A specific combination of propionyl-L-carnitine 250 mg, niacin 20 mg, and arginine 2500 mg daily.
- For a disease that causes curved, painful erections (Peyronie disease): 2 grams of propionyl-L-carnitine daily in combination with injections of a medication called verapamil.
- For a type of inflammatory bowel disease (ulcerative colitis): 0.5-1 gram of propionyl-L-carnitine twice daily.
- For leg pain during exercise due to poor blood flow (intermittent claudication): Healthcare providers give propionyl-L-carnitine with a needle in the vein (by IV).
12761 Benvenga S, Amato A, Calvani M, Trimarchi F. Effects of carnitine on thyroid hormone action. Ann N Y Acad Sci 2004;1033:158-67. View abstract.
Amico-Roxas M, Caruso A, Cutuli VM, et al. Inhibitory effects of propionyl-L-carnitine on plasma extravasation induced by irritants in rodents. Drugs Exp Clin Res 1993;19:213-7. View abstract.
Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291-9. View abstract.
Anon. Carnitor (levocarnitine) package insert. Sigma-Tau Pharmaceuticals Inc, Gaithersburg, MD. December 1999.
Bachmann HU, Hoffmann A. Interaction of food supplement L-carnitine with oral anticoagulant acenocoumarol. Swiss Med Wkly 2004;134:385.
Barditch-Crovo P, Toole J, Hendrix CW, et al. Anti-human immunodeficiency virus (HIV) activitiy, safety, and pharmacokinetics of adefovir dipivoxyl (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997;176:406-13. View abstract.
Bartels GL, Remme WJ, den Hartog FR, et al. Additional anti-ischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther 1995;9:749-53. View abstract.
Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995;26:1411-6. View abstract.
Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J 1992;13:251-5. View abstract.
Brotzu G, Fadda AM, Manca ML, et al. A liposome-based formulation containing equol, dihomo-?-linolenic acid and propionyl-l-carnitine to prevent and treat hair loss: A prospective investigation. Dermatol Ther. 2019 Jan;32(1):e12778. View abstract.
Campos Y, Arenas J. Muscle carnitine deficiency associated with zidovudine-induced mitochondrial myopathy. Ann Neurol 1994;36:680-1. View abstract.
Cao Y, Wang YX, Liu CJ, et al. Comparison of pharmacokinetics of L-carnitine, acetyl-L-carnitine and propionyl-L-carnitine after single oral administration of L-carnitine in healthy volunteers. Clin Invest Med 2009;32:E13-9. View abstract.
Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994;15:1267-73. View abstract.
Caruso A, Cutuli VM, De Bernardis E, et al. Protective effect of propionyl-L-carnitine against PAF-induced rat paw oedema. Pharmacol Res 1995;31:67-72. View abstract.
Castro-Gago M, Eiris-Punal J, Novo-Rodriguez MI, et al. Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital. J Child Neurol 1998;13:546-9. View abstract.
Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002;89:895-900. View abstract.
Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004;63:641-6. View abstract.
Cherchi A, Lai C, Onnis E, et al. Propionyl carnitine in stable effort angina. Cardiovasc Drugs Ther 1990;4:481-6. View abstract.
Chiddo A, Gaglione A, Musci S, et al. Hemodynamic study of intravenous propionyl-L-carnitine in patients with ischemic heart disease and normal left ventricular function. Cardiovasc Drugs Ther 1991;5 Suppl 1:107-11. View abstract.
Coulter DL. Carnitine, valproate, and toxicity. J Child Neurol 1991;6:7-14. View abstract.
Coulter DL. Prevention of hepatotoxicity recurrence with valproate monotherapy and carnitine. Ann Neurol 1988;24:301.
Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L-carnitine on peripheral arterial obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res 1999;25:29-36. View abstract.
Dalakas MC, Leon-Monzon ME, Bernardini I, et al. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994;35:482-7. View abstract.
De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia 1998;39:1216-25. View abstract.
Deeks SG, Collier A, Lalezari J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997;176:1517-23. View abstract.
Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003;42:941-67. View abstract.
Ferrari R, De Giuli F. The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. J Card Fail 1997;3:217-24. View abstract.
Freeman JM, Vining EPG, Cost S, Singhi P. Does carnitine administration improve the symptoms attributed to anticonvulsant medications? A double-blinded, crossover study. Pediatrics 1994;93:893-5. View abstract.
Gentile V, Vicini P, Prigiotti G, et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004;20:1377-84. View abstract.
Georgala S, Schulpis KH, Georgala C, Michas T. L-carnitine supplementation in patients with cystic acne on isotretinoin therapy. J Eur Acad Dermatol Venereol 1999;13:205-9. View abstract.
Georges B, Galland S, Rigault C, et al. Beneficial effects of L-carnitine in myoblastic C2C12 cells. Interaction with zidovudine. Biochem Pharmacol 2003;65:1483-8.. View abstract.
Gianfrilli D, Lauretta R, Di Dato C, et al. Propionyl-L-carnitine, L-arginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. Andrologia 2012;44 Suppl 1:600-4. View abstract.
Heuberger W, Berardi S, Jacky E, et al. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-8. View abstract.
Hiatt WR, Creager MA, Amato A, Brass EP. Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. J Cardiopulm Rehabil Prev 2011;31:125-32. View abstract.
Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-22.. View abstract.
Hirose S, Mitsudome A, Yasumoto S, et al. Valproate therapy does not deplete carnitine levels in otherwise healthy children. Pediatrics 1998;101:E9 (abstract). View abstract.
Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989;2:469-73. View abstract.
Hug G, McGraw CA, Bates SR, et al. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr 1991;119:799-802. View abstract.
Jacobs PL, Goldstein ER, Blackburn W, et al. Glycine propionyl-L-carnitine produces enhanced anaerobic work capacity with reduced lactate accumulation in resistance trained males. J Int Soc Sports Nutr 2009;6:9. View abstract.
Jacobs PL, Goldstein ER. Long-term glycine propionyl-l-carnitine supplementation and paradoxical effects on repeated anaerobic sprint performance. J Int Soc Sports Nutr 2010;7:35. View abstract.
Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy. J Am Med Assoc 1999;282:2305-12. View abstract.
Krahenbuhl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 1997;25:148-53. View abstract.
Krahenbuhl S. Carnitine metabolism in chronic liver disease. Life Sci 1996;59:1579-99. View abstract.
Kurul S, Dirik E, Iscan A. Serum carnitine levels during oxcarbazepine and carbamazepine monotherapies in children with epilepsy. J Child Neurol 2003;18:552-4. View abstract.
Laker MF, Green C, Bhuiyan AK, Shuster S. Isotretinoin and serum lipids: studies on fatty acid, apolipoprotein and intermediary metabolism. Br J Dermatol 1987;117:203-6. View abstract.
Luo T, Li J, Li L, et al. A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. Thromb Res 2013;132:427-32. View abstract.
Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-4. View abstract.
Marthaler NP, Visarius T, Kupfer A, Lauterburg BH. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol 1999;44:170-2. View abstract.
Martinez E, Domingo P, Roca-Cusachs A. Potentiation of acenocoumarol action by L-carnitine. J Intern Med 1993;233:94.
Merra G, Gasbarrini G, Laterza L, et al. Propionyl-L-carnitine hydrochloride for treatment of mild to moderate colonic inflammatory bowel diseases. World J Gastroenterol 2012;18:5065-71. View abstract.
Mikhailova TL, Sishkova E, Poniewierka E, et al. Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther 2011;34:1088-97. View abstract.
Mintz M. Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome. J Child Neurol 1995;10:S40-4. View abstract.
Noble S, Goa KL. Adefovir dipivoxil. Drugs 1999;58:479-87. View abstract.
Opala G, Winter S, Vance C, et al. The effect of valproic acid on plasma carnitine levels. Am J Dis Child 1991;145:999-1001. View abstract.
Persico G, Amato B, Aprea G, et al. The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study. Drugs Exp Clin Res 1995;21:187-98. View abstract.
Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000;34:630-8. View abstract.
Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 2004;1033:30-41. View abstract.
Riva R, Albani F, Gobbi G, et al. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia 1993;34:184-7. View abstract.
Schlenzig JS, Charpentier C, Rabier D, et al. L-carnitine: a way to decrease cellular toxicity of ifosfamide? Eur J Pediatr 1995;154:686-7. View abstract.
Scioli MG, Lo Giudice P, Bielli A, et al. Propionyl-l-carnitine enhances wound healing and counteracts microvascular endothelial cell dysfunction. PLoS One. 2015;10:e0140697. View abstract.
Scioli MG, Stasi MA, Passeri D, et al. Propionyl-l-carnitine is efficacious in ulcerative colitis through its action on the immune function and microvasculature. Clin Transl Gastroenterol 2014;5:e55. View abstract.
Sekas G, Paul HS. Hyperammonemia and carnitine deficiency in a patient receiving sulfadiazine and pyrimethamine. Am J Med 1993;95:112-3. View abstract.
Shapira Y, Gutman A. Muscle carnitine deficiency in patients using valproic acid. J Pediatrics 1991;118:646-9. View abstract.
Siliprandi N, Di Lisa F, Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991;5 Suppl 1:11-5. View abstract.
Stanley CA. Carnitine deficiency disorders in children. Ann N Y Acad Sci 2004;1033:42-51. View abstract.
Thom H, Carter PE, Cole GF, et al. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs. Dev Med Child Neurol 1991;33:795-802. View abstract.
Tsoko M, Beauseigneur F, Gresti J, et al. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of L-carnitine by D-carnitine and a gamma- butyrobetaine hydroxylase inhibitor. Biochem Pharmacol 1995;49:1403-10. View abstract.
Van Wouwe JP. Carnitine deficiency during valproic acid treatment. Int J Vitam Nutr Res 1995;65:211-4. View abstract.
Vance CK, Vance H, Winter SC, et al. Control of valproate-induced hepatotoxicity with carnitine. Ann Neurol 1989;26:456.
Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med 2004;66:276-82. View abstract.
Winter SC, Szabo-Aczel S, Curry CJR, et al. Plasma carnitine deficiency: Clinical observations in 51 pediatric patients. Am J Dis Child 1987;141:660-5. View abstract.
Wiseman LR, Brogden RN. Propionyl-L-carnitine. Drugs Aging 1998;12:243-8; discussion 249-50. View abstract.
Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 1999;290:1482-92. View abstract.
Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence? Acta Paediatr 1995;84:93-5. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.